

University of Groningen

## Acute promyelocytic leukemia

Ammatuna, Emanuele; van Doesum, Jaap

*Published in:*  
Leukemia & Lymphoma

*DOI:*  
[10.1080/10428194.2020.1869227](https://doi.org/10.1080/10428194.2020.1869227)

**IMPORTANT NOTE:** You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below.

*Document Version*  
Publisher's PDF, also known as Version of record

*Publication date:*  
2021

[Link to publication in University of Groningen/UMCG research database](#)

*Citation for published version (APA):*

Ammatuna, E., & van Doesum, J. (2021). Acute promyelocytic leukemia: if you wait it is too late. *Leukemia & Lymphoma*, 62(6), 1538. <https://doi.org/10.1080/10428194.2020.1869227>

### Copyright


Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).

The publication may also be distributed here under the terms of Article 25fa of the Dutch Copyright Act, indicated by the "Taverne" license. More information can be found on the University of Groningen website: <https://www.rug.nl/library/open-access/self-archiving-pure/taverne-amendment>.

### Take-down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

*Downloaded from the University of Groningen/UMCG research database (Pure): <http://www.rug.nl/research/portal>. For technical reasons the number of authors shown on this cover page is limited to 10 maximum.*



## Acute promyelocytic leukemia: if you wait it is too late

Emanuele Ammatuna & Jaap van Doesum


To cite this article: Emanuele Ammatuna & Jaap van Doesum (2021): Acute promyelocytic leukemia: if you wait it is too late, *Leukemia & Lymphoma*, DOI: [10.1080/10428194.2020.1869227](https://doi.org/10.1080/10428194.2020.1869227)

To link to this article: <https://doi.org/10.1080/10428194.2020.1869227>



Published online: 06 Jan 2021.




[Submit your article to this journal](#) 



Article views: 24



[View related articles](#) 



[View Crossmark data](#) 

CORRESPONDENCE



## Acute promyelocytic leukemia: if you wait it is too late

Emanuele Ammatuna and Jaap van Doesum

Department of Hematology, University Medical Centre Groningen, Groningen, The Netherlands

**ARTICLE HISTORY** Received 9 October 2020; revised 17 November 2020; accepted 30 November 2020

Avgerinou and coauthors describe a case of cytogenetically cryptic and fish-negative acute promyelocytic leukemia (APL) which was finally detected by RT-PCR. The authors highlight the importance of RT-PCR for the detection of the PML/RARA rearrangement. Lastly they assert that the results of RT-PCR is vital for prompt initiation of all-trans-retinoic acid (ATRA) based treatment [1].

We agree with the authors that RT-PCR is mandatory in the workup of APL for two reasons: 1) To confirm the presence of the PML-RARA fusion gene, 2) to monitor the disease during treatment.

As a contribution to this case we would like to emphasize that RT-PCR is not necessary for initiating ATRA therapy. APL has a good prognosis, but is a medical emergency. Early hemorrhagic death is still the major cause of induction failure. For this reason, guidelines recommend initiating ATRA therapy based exclusively on clinical suspicion without waiting for diagnosis confirmation. Next to ATRA based treatment it is of great importance to start supportive care to maintain the fibrinogen concentration above 100–150 mg/dl, the platelet count above  $30\text{--}50 \times 10^9/\text{L}$  [2].

In addition, RT-PCR and cytogenetic tests have a longer turnaround time than is necessary to make rapid treatment decisions. On the contrary the immunofluorescent analysis of the PML distribution pattern with the anti-PML monoclonal antibody PG-M3 is easy to perform, requires a peripheral blood or marrow smear and has a turnaround time of 2 h. That means, it takes only 2 h to confirm the diagnosis of APL and predict sensitivity to ATRA. In fact, as previously described in other reports [3–5], the identification of a characteristic micro-speckled nuclear pattern of the PML correlates with 100% concordance with the presence of the PML-RARA fusion gene detected by reverse-transcription polymerase chain reaction and indicate responsiveness to ATRA/ATO.

It has to be highlighted that in the presence of a strong suspicion of APL and concomitant absence of a

characteristic micro-speckled nuclear pattern, ATRA therapy should not be stopped until genetic tests are done. This because there are rare APL cases with different RARA fusion partners that could still be responsive to ATRA treatment.

In summary, by the suspicion of an APL, ATRA and supportive care should promptly been started without waiting for confirmation tests. The most rapid test to show ATRA sensitivity is the immunofluorescence using the anti-PML antibody. This technic can be particularly advantageous in clinical settings, such as community hospitals or in under-resourced countries where other methods are not promptly available.

### Disclosure statement

No potential conflict of interest was reported by the author(s).

### References

- [1] Avgerinou G, Katsibardi K, Filippidou M, et al. Cytogenetically cryptic and fish negative PML/RARA rearrangement in acute promyelocytic leukemia detected by RT-PCR. *Leuk Lymphoma*. 2020;10:1–3.
- [2] Lo-Coco F, Ammatuna E, Montesinos P, et al. Acute promyelocytic leukemia: recent advances in diagnosis and management. *Semin Oncol*. 2008;35(4):401–409.
- [3] Falini B, Flenghi L, Fagioli M, et al. Immunocytochemical diagnosis of acute promyelocytic leukemia (M3) with the monoclonal antibody PG-M3 (anti-PML). *Blood*. 1997;90(10):4046–4053.
- [4] Gomis F, Sanz J, Sempere A, et al. Immunofluorescent analysis with the anti-PML monoclonal antibody PG-M3 for rapid and accurate genetic diagnosis of acute promyelocytic leukemia. *Ann Hematol*. 2004;83(11):687–690.
- [5] Gupta SK, Sazawal S, Mahapatra M, et al. Evaluation of PG-M3 antibody in the diagnosis of acute promyelocytic leukemia. *Eur J Clin Invest*. 2010;40(10):960–962.